There is some debate as to whether GLP-1 agonist drugs like Wegovy can lead to unhealthy muscle mass loss in addition to ...

In the US, liraglutide, semaglutide, and tirzepatide are currently under investigation for their ability to stimulate weight ...

A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and accompanying ...

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

For the 12% of adults in the U.S. now taking a weight-loss medication that targets the GLP-1 and/or GIP hormones to restrict ...

DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format KELOWNA, BC / ACCESSWIRE / November ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

The diabetes drug, Ozempic, has been in the headlines, causing quite a stir. Senior writer for Drugwatch.com, Terry Turner, ...

Ken Griffin started the Citadel hedge fund in 1990. In the third quarter, Griffin and Citadel more than tripled its stake in ...